Tech Company Financing Transactions
Kailo Pharma Funding Round
Kailo Pharma, based in Nazareth, secured $2 million in funding from Israel Innovation Authority.
Transaction Overview
Company Name
Announced On
3/30/2026
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its treatments towards clinical trials.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
16 Wadi Al-Haj
Nazareth, 1603612
Israel
Nazareth, 1603612
Israel
Phone
Undisclosed
Email Address
Not Recorded
Overview
Kailo Pharma is a clinical-stage biopharmaceutical startup headquartered in Nazareth, Israel, dedicated to developing the first drug specifically designed to treat the root cause of Post-Traumatic Stress Disorder (PTSD). The company's mission is to redefine PTSD treatment by moving beyond symptom management (like antidepressants or anti-anxiety meds) to directly target the brain's memory-related mechanisms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Osnat On
Browse more venture capital transactions:
Prev: 3/30/2026: EPG Data Center Module venture capital transaction
Next: 3/30/2026: Mistral AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs